According to Zacks, “Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women’s health. The company’s product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey. “
Several other equities research analysts have also issued reports on OSMT. Wells Fargo & Co reaffirmed a buy rating on shares of Osmotica Pharmaceuticals in a research note on Friday, August 9th. Barclays assumed coverage on Osmotica Pharmaceuticals in a research note on Tuesday, June 11th. They set an overweight rating and a $11.00 price objective on the stock. ValuEngine upgraded Osmotica Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, Jefferies Financial Group set a $10.00 target price on Osmotica Pharmaceuticals and gave the company a buy rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $13.00.
Osmotica Pharmaceuticals stock opened at $3.20 on Friday. Osmotica Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $9.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.49 and a current ratio of 1.78. The stock has a market cap of $154.56 million and a P/E ratio of -6.27. The firm’s fifty day moving average price is $3.09 and its 200-day moving average price is $3.90.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its earnings results on Thursday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.06. The company had revenue of $57.53 million during the quarter, compared to analyst estimates of $57.90 million. Osmotica Pharmaceuticals had a negative net margin of 97.91% and a negative return on equity of 32.14%. On average, analysts predict that Osmotica Pharmaceuticals will post -0.25 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in OSMT. Citadel Advisors LLC bought a new stake in shares of Osmotica Pharmaceuticals in the 2nd quarter worth approximately $120,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Osmotica Pharmaceuticals during the second quarter valued at approximately $142,000. Sofinnova Investments Inc. raised its holdings in shares of Osmotica Pharmaceuticals by 107.5% during the second quarter. Sofinnova Investments Inc. now owns 525,198 shares of the company’s stock valued at $1,996,000 after acquiring an additional 272,109 shares in the last quarter. Northern Trust Corp lifted its stake in Osmotica Pharmaceuticals by 5.6% in the second quarter. Northern Trust Corp now owns 99,449 shares of the company’s stock worth $378,000 after acquiring an additional 5,230 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in Osmotica Pharmaceuticals by 277.5% in the second quarter. Acadian Asset Management LLC now owns 53,846 shares of the company’s stock worth $206,000 after acquiring an additional 39,584 shares during the period. Hedge funds and other institutional investors own 7.01% of the company’s stock.
Osmotica Pharmaceuticals Company Profile
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Recommended Story: How does a security become overbought?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.